1. Generics Bulletin
  3. >>Strategy

Despite Landing Biggest PBM Formularies, Celltrion’s Zymfentra Not Listed By US Insurers

Zymfentra Is The First FDA-Approved Subcutaneous Formulation Of Infliximab

 
• By Urtė Fultinavičiūtė

Celltrion gave updates on several business aspects and reassured its shareholders that the delayed insurance listing for Zymfentra will not affect its set annual sales goal.

Person standing next to a gap in a path
(Shutterstock)

Getting on the three biggest pharmacy benefit managers’ formulary lists in the US within half a year of a product launch is a big achievement, but even then, it is not guaranteed that the insurers under the PBMs will list it. This was the case for Celltrion.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Generics Bulletin